Developing New Version Of Sputnik Vaccine Adapted To 'Omicron': Russia
The Russian Direct Investment Fund (RDIF), which supported the vaccine's development by the state-run Gamaleya Center, said that the centre "has already begun developing the new version of Sputnik vaccine adapted to Omicron."
The backers of the Russian Covid-19 vaccine Sputnik V said Monday that the jab is effective against the new 'Omicron' coronavirus variant but they were also developing an adapted booster.
The Russian Direct Investment Fund (RDIF), which supported the vaccine's development by the state-run Gamaleya Center, said that the centre "has already begun developing the new version of Sputnik vaccine adapted to 'Omicron'."
"In an unlikely case such modification is needed, the new Sputnik 'Omicron' version can be ready for mass-scale production in 45 days," RDIF said in a statement.
"Several hundred million Sputnik 'Omicron' boosters can be provided to international markets already by February 20, 2022 with over 3 billion doses available in 2022."
The promise comes after the US pharmaceutical company Moderna said Friday that it will develop a booster shot against the highly mutated strain of the coronavirus, which is more transmissible than the dominant Delta variant.
Germany's BioNTech and US drugmaker Pfizer said the same day that they expect data "in two weeks at the latest" to show if their jab can be adjusted.
Last week RDIF said Sputnik V provides longer immunity against the coronavirus than Western jabs using messenger RNA (mRNA) technology.
It added that the Sputnik vaccine is 80 percent effective against the coronavirus between six and eight months after the second dose.
No independent study has confirmed the claim.
Russia registered Sputnik V last August ahead of large-scale clinical trials, prompting concern among experts over the fast-tracked process.
But it was since declared safe and over 90 percent effective in a report published by leading medical journal The Lancet.
The RDIF says its two-dose vaccine has been approved in 71 countries and that it has applied for registration in the European Union.
Earlier this summer several Latin American countries that have relied on the Russian vaccine to protect their populations complained to Moscow about delivery delays.
The Russian Direct Investment Fund (RDIF), which supported the vaccine's development by the state-run Gamaleya Center, said that the centre "has already begun developing the new version of Sputnik vaccine adapted to 'Omicron'."
"In an unlikely case such modification is needed, the new Sputnik 'Omicron' version can be ready for mass-scale production in 45 days," RDIF said in a statement.
"Several hundred million Sputnik 'Omicron' boosters can be provided to international markets already by February 20, 2022 with over 3 billion doses available in 2022."
The promise comes after the US pharmaceutical company Moderna said Friday that it will develop a booster shot against the highly mutated strain of the coronavirus, which is more transmissible than the dominant Delta variant.
Germany's BioNTech and US drugmaker Pfizer said the same day that they expect data "in two weeks at the latest" to show if their jab can be adjusted.
Last week RDIF said Sputnik V provides longer immunity against the coronavirus than Western jabs using messenger RNA (mRNA) technology.
It added that the Sputnik vaccine is 80 percent effective against the coronavirus between six and eight months after the second dose.
No independent study has confirmed the claim.
Russia registered Sputnik V last August ahead of large-scale clinical trials, prompting concern among experts over the fast-tracked process.
But it was since declared safe and over 90 percent effective in a report published by leading medical journal The Lancet.
The RDIF says its two-dose vaccine has been approved in 71 countries and that it has applied for registration in the European Union.
Earlier this summer several Latin American countries that have relied on the Russian vaccine to protect their populations complained to Moscow about delivery delays.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
